JGC
TGTX icon

J. Goldman & Co’s TG Therapeutics TGTX Stock Holding History

J. Goldman & Co’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-54,000
Closed -$1.34M – 478
2023
Q2 		$1.34M Buy
+54,000
New +$1.39M 0.05% 233

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

J. Goldman & Co's TGTX Position: Q1 2026 in Review

J. Goldman & Co increased its TG Therapeutics (TGTX) stake by 9.2% in Q1 2026, buying an estimated $121K and bringing the position to 48,235 shares worth $1.6M. The position accounts for 0.05% of the portfolio, ranked #358.

J. Goldman & Co first reported a position in TGTX in Q1 2020 and has held it in 12 quarters since. The position peaked at $4.45M in Q2 2023. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • J. Goldman & Co held 48,235 shares of TG Therapeutics worth $1.6M as of Q1 2026.
  • J. Goldman & Co bought 4,044 TG Therapeutics shares in Q1 2026, an estimated $121K.
  • TG Therapeutics made up 0.05% of J. Goldman & Co's portfolio in Q1 2026, its #358 holding.
  • J. Goldman & Co first reported a position in TG Therapeutics in Q1 2020 and has held it in 12 quarters since.
  • J. Goldman & Co's TG Therapeutics position peaked at $4.45M in Q2 2023.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.